Progress of InnFocus’ MicroShunt

Russ Trenary, president and CEO of InnFocus, updated OIS@ASCRS on the progress of MicroShunt, which the company says could be the first and only surgical device/procedure to provide treatment for mild-, moderate-, and severe-stage primary open angle glaucoma. Santen acquired InnFocus in 2016.